Navigation Links
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
Date:11/2/2009

FREMONT, Calif., Nov. 2 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will present a case history of QPI-1002, the first systemically administered synthetic siRNA, at the Joint Symposium of the 5th Annual Meeting of Oligonucleotide Therapeutics Society and the 19th Antisense Symposium in Fukuoka, Japan, November 3-6, 2009. The company also announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, will participate in the RNAi for Developing Targeted Therapeutics track at this year's CHI Discovery on Target Conference in Boston, November 2-4, 2009.

Dr. Thompson's presentation will be part of a session titled, "Clinical Studies and Therapeutic Development," which will be held on Thursday, November 5. The case study on QPI-1002 will detail Quark's progress in its independent development of the first systemic administration of a synthetic siRNA in humans, results from Quark's IND-enabling efficacy and toxicology studies and the largest cGMP manufacture of synthetic siRNA of its time. Dr. Feinstein's presentation, titled "Use of siRNA for Amelioration of Aseptic Lung Inflammatory Conditions," will take place on Wednesday, November 4 and will present Quark's preclinical studies for aseptic lung inflammation.

Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark, said, "Drs. Thompson and Feinstein's presentations demonstrate Quark's leadership and continued innovation in the discovery and development of siRNA therapeutics. Quark's strength in preclinical discovery has promoted development of a robust pipeline that provides our company with growth opportunities within a broad range of therapeutic areas. We are nicely positioned to progress our clinical stage drug candidates, including t
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
2. Quark Pharmaceuticals Presents at Asia TIDES Conference
3. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/19/2014)... BIRMINGHAM, Ala. , Aug. 19, 2014  The Alabama ... re-affirmed that patients can sue drug makers who mislead doctors ... cause harmful side‑effects.  The case is Weeks v. Wyeth, and ... drug makers in that same case last year. Heninger Garrison ... represent the patient in the case, Danny Weeks ...
(Date:8/19/2014)... -- Minimally Invasive Devices Inc. (MID), a ... that Mitsubishi Corporation has formally agreed to exclusively distribute ... Japan . MID anticipates that FloShield will ... in the second half of 2015. ... Storz GMBH & Co. (endoscopic instruments and devices) in ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
... achieve undetectable viral load in Phase,IIa trial within ... care, SAN FRANCISCO, Nov. 1 New ... protease inhibitor (PI) being,developed by Tibotec BVBA for ... Tibotec will present findings from three TMC435 studies,including ...
... Higher Sustained Virological Response Rates Recognized as Marker ... 1 A new,independently-conducted study being presented at ... the Study of Liver Diseases (AASLD) shows that,PEGASYS(R) ... response (SVR) rates for hepatitis C patients as,compared ...
Cached Medicine Technology:Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7
(Date:8/20/2014)... August 20, 2014 Doctors at the University ... wipe out mesothelioma in laboratory mice by injecting them with ... posted details of the study on its website. Click ... with Hong Kong University’s AIDS Institute of Microbiology created a ... or PD-1. By altering DNA, the vaccine is designed to ...
(Date:8/20/2014)... Today, Zane Benefits, the #1 Online ... for 2015. , According to Zane Benefits, with open ... employees are encouraged to start thinking about their healthcare ... open enrollment period will run from November 15, 2014 ... can purchase a new individual health insurance policy, or ...
(Date:8/20/2014)... 20, 2014 The report “Automotive ... - A Global Analysis: by Geography - Trends ... classifies and defines automotive airbag and seatbelt market ... highlights potential growth opportunities in the coming years ... market drivers, restrains, growth indicators, challenges, legislation trends, ...
(Date:8/20/2014)... August 20, 2014 In a recent ... a University College London (UCL) study showed that dental ... method of brushing teeth was the most effective. Analysis ... different tooth-brushing techniques were frequently recommended, but none were ... for Cosmetic Dentistry, experienced cosmetic dentist Dr. ...
(Date:8/20/2014)... Hope For The Warriors® is excited to announce ... in Washington, DC on Thursday, October 2, 2014 at ... the courage of our wounded service members, their families, ... Got Heart, Give Hope® Celebration will benefit Hope For ... sense of self, restoring the family unit, and restoring ...
Breaking Medicine News(10 mins):Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2
... May 19 Towards the Electronic,Patient Record ... interface terminology,announced today its next-generation interface terminology ... terminologies access to all of,IMO,s terminology knowledge ... algorithms optimized for millisecond response times in ...
... Sciences (OTC,Bulletin Board: DSCI), a provider of advanced ... Burn Dressing, its flagship wound care,product, was profiled ... Reporter Lisa Thomas-Laury examines the use of ... Leonard Abrams Center for Advanced Wound,Healing of the ...
... Health, Inc., one of,the nation,s largest public/private health ... provider of software agent,technologies for health information exchange, ... clinicians at the point of care., Shared ... the clinical,interface capabilities of what is already one ...
... Should Be ,Wake-Up Call, for Doctors and Women, WASHINGTON, ... coronary artery disease are significantly less likely than,men to be ... WomenHeart - the national coalition for women with heart,disease -- ... sure,that women are getting the care that they need., ...
... May 19 Edifecs, the leader in ... EDS has,selected the Edifecs Healthcare Accelerator Suite ... health care transactions in both,real-time and batch ... of the,EDS MetaVance(R) Administration and Finance System., ...
... of Liverpool has performed a groundbreaking operation on a chimp ... dogs. , The three year-old chimp called Janet was rescued ... in a chimpanzee reserve supported by the Cameroon Wildlife Aid ... because a bone in her forearm - the ulna - ...
Cached Medicine News:Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 2Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 3Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 4Health News:Derma Sciences' MEDIHONEY(TM) Profiled By ABC News' Philadelphia Affiliate 2Health News:Shared Health(R) and Novo Innovations Partner for Improved Information-Sharing of Clinical Health Records 2Health News:Shared Health(R) and Novo Innovations Partner for Improved Information-Sharing of Clinical Health Records 3Health News:Study: Doctors Significantly Less Likely to Provide Women with Treatments to Prevent Heart Attacks 2Health News:EDS Selects Edifecs Healthcare Accelerator Suite for Claims Processing Solution 2Health News:Surgeon operates to rescue chimp with rare deformity 2
... and model 1488 active-fixation leads are among ... the unsurpassed handling advantages, performance, and reliability ... active-fixation leads. Implantable with a 7 F ... Tendril SDX lead is designed to lower ...
... CheckPoint is an automated, wireless, computerized ... alert system for refrigerator, freezer, incubator ... recorders, data loggers and manual temperature ... an existing PC and comes complete ...
... This requiring no water for ... hand hygiene to physically clean ... is either not an option ... allows you to return to ...
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
Medicine Products: